ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021

Rhea-AI Summary

ClearPoint Neuro (Nasdaq: CLPT) announced its Q1 2021 financial results release date set for May 11, 2021, after market close. The live broadcast for the results will occur at 4:30 PM ET on the same day. Interested parties can access the call online or by phone. ClearPoint Neuro focuses on improving patient quality of life through precise therapies for neurological disorders, with FDA-cleared products used in over 60 clinical sites. The company’s partnerships include 25 biologics and drug delivery companies, supporting over 4,000 cases.

Positive

• ClearPoint Neuro's products are FDA-cleared and CE-marked, enhancing market credibility.
• The company has established partnerships with 25 biologics and drug delivery firms, indicating strong industry collaboration.
• The ClearPoint Neuro Navigation System is operational in over 60 clinical sites across multiple regions.

Negative

• Risks related to COVID-19 could influence future sales and market acceptance of the company's products.
• Actual results may vary significantly from management's forward-looking statements due to various uncertainties.

SOLANA BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 first quarter, which ended March 31, 2021, on Tuesday, May 11, 2021, after the market close.

Investors and analysts are invited to listen to a live broadcast review of the Company's 2021 first quarter financial results on Tuesday, May 11, 2021 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here or by visiting the Company's website at www.clearpointneuro.com and selecting “Investors” / “News” / “IR Calendar.” Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until Friday, June 11, 2021 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at www.clearpointneuro.com, on the “Investor Relations” page.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company’s SmartFlow^® cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission, and in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021, which the Company intends to file with the Securities and Exchange Commission on or before May 17, 2021.

FAQ

When will ClearPoint Neuro release its first quarter financial results for 2021?

ClearPoint Neuro will release its Q1 2021 financial results on May 11, 2021, after market close.

What time is the ClearPoint Neuro conference call for Q1 financial results?

The conference call for ClearPoint Neuro's Q1 financial results will be held at 4:30 PM ET on May 11, 2021.

How can I access the ClearPoint Neuro financial results conference call?

You can access the call online or by phone at (877) 407-9034 (U.S.) or (201) 493-6737 (International).

What is the significance of ClearPoint Neuro's partnerships with biologics companies?

ClearPoint Neuro is collaborating with 25 biologics and drug delivery companies, which supports its growth and market presence.